Press release from Companies

Published: 2021-07-27 12:16:51

Double Bond Pharmaceutical International AB: DBP International AB: next purchase order for Temodex to Columbia

 

Double Bond Pharmaceutical International AB (publ) ("DBP" or ”Company”) which is a distributor of Temodex continues to work with its partners to register the product in Latin America and China. Today, DBP has received a purchase order for 3 Temodex vials worth approximately $ 10k from its partner in Columbia.

"There is a great interest in Temodex/SI-053 in different parts of the world and while we are commencing clinical trials phase I with SI-053 in EU, we will commercialize Temodex on other available markets. With the current order we are happy to provide doctors and patients with brain cancer our innovative product" – commented Igor Lokot, CEO of DBP. “Latin America is a large market and can generate a lucrative business for the Company” – Igor Lokot adds.


 

__________________________________________________________________

Information about Double Bond Pharmaceutical International AB: DBP is a pharmaceutical company with the primary focus on development of therapies against cancer based on the company’s own developed drug delivery technology BeloGal®. The company was granted Orphan Drug Designation status by European Medicines Agency (EMA) in June 2015 for its first product, SA-033, for treatment of hepatoblastoma. Double Bond Pharmaceutical acquired rights to Temodex, a drug registered in Belarus for treatment of brain tumours, in October 2015, and was granted Orphan Drug Designation status by EMA for in July 2016 for this formulation of temozolomide for the treatment of glioma. The formulation is now being further developed for registration in EU and globally and has a working name SI-053 in DBP pipeline.

More about Temodex/SI-053: Temodex, which is a locally acting formulation of temozolomide developed by RI PCP in Minsk, Belarus, is registered for marketing as the first-line treatment of glioblastoma within Belarus since 2014. Temodex was acquired by DBP in autumn 2015 and is now being prepared under the name SI-053 to pass through all the tests and trials required for registration within the EU and globally.

Video presentation: https://youtu.be/iweOQPq316o

____________________________________________________________________

Full Company Name:   Double Bond Pharmaceutical International AB (publ)

Corporate identity:       556991-6082

Stock short name:       DBP B

Share ISIN code:          SE0007185525

For more info, contact

Igor Lokot, CEO

Homepage: http://www.doublebp.com/

E-mail: info@doublebp.com

Follow us on LinkedIn and Twitter!

_______________________________________________________________________________

Läs mer hos Cision
Read more about Double Bond Pharmaceutical International AB

Subscription